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Background: Food-borne infections cause huge economic and human life losses worldwide. The most common
contaminants of foods include Listeria monocytogenes Salmonellae and Staphylococcus aureus. L. monocytogenes is
most notorious due to its tolerance to common food preservation methods and the risks it poses, including higher
fatality rates. Safer, more efficacious control methods are thus needed. Along with food-borne pathogens, lactic acid
bacteria (LAB) can also be found in foods. Some LAB isolates inhibit pathogenic bacteria by various mechanisms,
including by production of antimicrobial metabolites.
Methods: The potential of cell-free culture supernatants (CFS) derived from broth cultures of selected local LAB and
yeast isolates, some of which were subjected to various treatments, were tested for inhibition of L. monocytogenes,
Salmonella spp. and S. aureus in in vitro culture by incorporating various proportions of the CFSs into the growth
medium concurrently with inoculation (co-cultures) or following limited proliferation after inoculation of the pathogens
(delayed cultures). The effects of the CFSs on various growth parameters were assessed.
Results: CFS from the LAB isolates were strongly inhibitory when co-cultured. The inhibitory activities were stable
following heat or protease treatment of the CFSs. Inhibitory activity was dependent primarily on active substance(s)
secreted into the supernatant. In all co-cultures, CFS proportion-dependent progressive decrease in the number of
colonies was observed and both growth rates and number of generations were reduced with significantly fewer
numbers of colony forming units, whereas generation times were significantly increased compared to those of controls.
Transfer from co-cultures to fresh broth showed inhibited cultures contained bacteria that can re-grow, indicating the
presence of viable bacteria that are undetectable by culture. Growth rates in CFS-treated delayed cultures were
also reduced to varying degrees with the number of colonies in some cultures being significantly less than the
corresponding control values. CFSs were active against both Gram-positive and –negative bacteria.
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Conclusions: Active metabolites produced and secreted by LAB into the growth medium were effective in
inhibiting the tested pathogens. Early addition of the CFSs was necessary for significant inhibition to occur.
Further studies will help make these findings applicable to food safety.
Keywords: Lactic acid bacteria, Listeria monocytogenes, Salmonella, Staphylococcus aureus, Inhibition, Cell-free
supernatant, InhibitionBackground
Food-borne infections cause huge economic losses, in
addition to morbidity and mortality. Listeria monocytogenes
and nontyphoidal Salmonella enterica ranked among
the top five identifiable pathogens causing these human
and economic losses [1]. A study estimated an aggre-
gate annual cost of 50–77 billion due to food-borne ill-
ness in the United States [2]. Staphlococcus aureus also
ranked among the top five pathogens that caused food-
borne illnesses in 2011 [3].
L. monocytogenes is exceptional in that it can tolerate
high salt concentrations, remains viable at temperatures
as low as 0°C, and is also difficult to eliminate by ordin-
ary disinfectants [4,5]. It can be found as a contaminant
in meat, milk and other food-processing facilities. Risk
groups in humans include immuno-compromised per-
sons and the elderly. The infection causes septicemia,
meningitis, encephalitis or abortion or stillbirth of neo-
nates, while gastroenteritis can occur in the general pub-
lic [6]. The infectious dose is unknown but the case
fatality rate has been reported to be 20-40% [6,7], which
is much higher than the fatality rate of salmonellosis, the
incidence rate of which is, in turn, much higher than
listeriosis [6,7].
As well as food-borne pathogens, lactic acid bacteria
(LAB) can also be found in various habitats including in
foods and drinks of plant and animal origins. Fermented
foods and drinks are particularly rich in their content of
LAB. LAB species of practical importance are usually
nonpathogenic and safe, at least in healthy and immuno-
competent people. Several reports have indicated that
the shelf-life of foods can be extended by LAB or LAB
metabolites [8-11]. Food safety is enhanced because of
the inhibitory actions of LAB on common food-borne
pathogens such as Escherichia coli O157::H7, Salmonella
spp. and Listeria monocytogenes. Inhibition of food-
borne pathogens by LAB can be mediated by competi-
tive exclusion or production of organic acids and anti-
microbial products such as hydrogen peroxide and
antimicrobial peptides (e.g., bacteriocins) [12-14]. These
products can be produced by some LAB and secreted
when grown in appropriate broth medium. Either live
LAB or their metabolic products can be used [14].
Moreover, the antimicrobial properties of some LAB or
their antimicrobial peptide products as well as theirvaccine potential may make them suitable candidates as
bio-therapeutic agents for human and animal applica-
tions [15-20]. Thus, selected LAB species with these and
additional qualities (termed probiotics, defined as live
microorganisms which, when administered in adequate
amounts confer health benefit on the host [21]) have
been developed.
In this work, we focused on the inhibitory effects of
metabolites of a collection of LAB and yeast isolates ob-
tained from local fermented foods and milk on some
common food-borne pathogens or standard strains. The
choice of these fermented foods and milk is based on
the fact that these are consumed regularly by the popu-
lation. The inhibitory effect of cell-free culture superna-
tants (CFS) from broth cultures of the selected isolates
on growth rates and colony-forming units of L. monocy-
togenes, Salmonella and S. aureus were tested following
various treatments of the CFS as described below.
Methods
Bacterial isolates and growth conditions
The sources of LAB used in this study were fermented
milk, ananas and a grain called Teff, which are import-
ant fermented foods consumed regularly in Ethiopia.
The fermentates were diluited in sterile PBS buffer,
pH 7.2 and, to obtain single colonies, 100 μL of the sixth
and seventh 10-fold serial dilutions were plated on De
Man, Rogosa, Sharpe (MRS) agar, followed by picking
single colonies at random and growing in MRS broth.
Incubations of both agar and broth cultures were at 37°C
at aerobic or anaerobic conditions. Combinations of stand-
ard tests (microscopy, cultural and biochemical) [22,23]
were used to tentatively identify the isolates. Cell pellets
from the MRS broth cultures were resuspended in MRS
broth containing 15% glycerol and aliquots were frozen for
use when needed. All media used here were from OXOID,
UK. In addition, while we were searching for a LAB isolate
from the ananas fermentate, a non-LAB isolate that was
found and later identified to be a yeast was used in the in-
hibition studies.
The bacteria tested for inhibition by the CFSs (target
strains) were Listeria monocytogenes (ATCC 19115),
Salmonella enterica subsp. enterica serovar Enteritidis
(ATCC 13076) and S. aureus (ATCC 25923), all type
strains. Another bacterial isolate used was MI1, an isolate
Mariam et al. BMC Research Notes 2014, 7:606 Page 3 of 9
http://www.biomedcentral.com/1756-0500/7/606from bovine milk identified to be Salmonella spp. by
tests including Gram staining, colonial morphology,
motility and growth on differentiating and selective media
(MacKonkey, XLD and Salmonella-Shigella agars), sugar
fermentation test with Biomerioux API20 (Biomerioux,
France) in comparison with the known properties of
Salmonella spp. The results of none of these tests
conducted on the milk isolate were similar to those of the
known properties of the possible contaminants of milk,
such as S. aureus, Listeria, E. coli, Brucella, Campylobacter
or Mycobacterium spp. [22,23].
L. monocytogenes was grown in tryptic soy broth (TSB)
or tryptic soy agar (TSA). Salmonellae and S. aureus
were grown in Luria Bertani (LB) broth or agar. When
applicable, agar media were supplemented with 0.5%
pyruvate to enhance detection of possible presence of
viable but nonculturable organisms.
Growth of strains for preparation of CFS
Seventeen isolates from the above sources were grown
in MRS broth as described above. The supernatant was
recovered by centrifugation at 3000 rpm in a Beckman
Allegra 6R (Beckman Coulter) centrifuge for 1 hr. CFSs
were obtained by passing the supernatants through
0.4 μm pore size filters and tested for inhibitory effect
on the tested bacteria (in co-cultures, please see below)
before adjusting the pH of the CFSs. Four isolates (total
LAB and Lactococcus sp. [both isolated from fermented
milk], Streptococcus thermophilus [isolated from Teff]
and a yeast species [isolated from ananas]) whose CFSs
inhibited the bacteria when tested individually were se-
lected based on this initial observation. These four iso-
lates were grown individually from frozen stock samples
in 20 mL MRS broth and incubating aerobically or an-
aerobically at 37°C. In addition, a cocktail made of a
mixed culture of these four isolates (Labmix) was also
grown in the same way as for the individual isolates.
After 18 h of incubation, an aliquot of 100 μL was trans-
ferred into 250 mL of MRS broth and incubated for
24 h. After centrifugation as above, each supernatant
was then divided into two portions and subjected suc-
cessively to the following treatments, further dividing
each supernatant into two in going from one treatment
to the next.
pH adjustment
The pH of the supernatants before pH adjustment were
in the range of 4.5-4.8. A portion of each supernatant
was subject to pH adjustment to 6.5 - 6.8.
Proteinase K treatment of supernatant
Portions of supernatants were treated with proteinase K
(BDH Biochemicals) at a concentration of 50 μg mL−1
for 1 hr at 37°C in a reaction mixture containing 0.5%SDS, 0.01 M Tris and 0.005 M EDTA [24]. Following
treatment, the enzyme was inactivated by addition of
phenylmethylsulfonyl fluoride. The supernatants were
filtered through 0.4 μm pore size filter.
Heat Treatment of CFS
To test if inhibitory activity was heat-stable or –sensitive,
portions were heat-treated (100°C for 1 hr).
Thus, for each isolate, four types of CFS derived from
it were tested for inhibitory activity: both pH-adjusted
and heat-treated (CFS1), pH-adjusted only (CFS2), heat-
treated only (CFS3), and neither pH-adjusted nor heat
treated (CFS4). CFS prepared as above was aliquoted
and stored at −20°C. A fresh aliquot was thawed and
used for experiments.
In addition to MRS broth, LAPTg broth was also used
to grow the LAB isolates and obtain the CFS. Catalase
treatment of the CFSs from LAPTg broth was also con-
ducted to test for possible involvement of hydrogen per-
oxide in inhibition which, if present, would be abolished
by the catalase tretament.
Test of CFS inhibitory effect
The CFSs were initially tested on the test bacteria L. mono-
cytogenes, Salmonellae and S. aureus by adding CFS to
12.5%, 25% or 50% proportions (v/v) in 5 mL final volume.
Intermediate CFS proportions were also included as
deemed necessary. In either case, 1 μL each of L. monocy-
togenes (~8.00 × 103 CFU mL−1), S. enterica (~2.60 ×
105 CFU mL−1), Salmonella (MI1) (~1.32 × 104 CFU mL−1)
or S. aureus (~1.30 × 104 CFU mL−1) from frozen stocks
were inoculated. The CFSs were added in two different
modes to make the 5 mL final volume according to
their percentage proportions: (i) Co-cultures, in which
CFS were added simultaneously with inoculation of
the test bacteria; (ii) Delayed cultures, in which broth
media were inoculated and incubated, followed by CFS
addition after 6 hrs of incubation. To obtain the rate of
growth of the target strains the turbidity was measured
using an optical density of 600 nm with a spectropho-
tometer Novaspec II (Pharmacia Biotech) as well as by
plating 1 μL of 10-fold serial dilutions of (i) the co-
cultures at time points day 0 (immediately after both
inoculation and CFS addition) and 3 days and (ii) the
delayed cultures at time points day 0 (immediately after
CFS addition, i.e., after 6 hrs of inoculation and incubation)
and 1.5 days. Growth controls for co-cultures included
cultures in 5 mL broth volumes without added CFS.
Cultures in which MRS broth was added instead of CFS
(to 50% v/v) were also included. Colonies were usually enu-
merated after 24 or 48 hrs on TSA agar (L. monocytogenes)
or LB agar (Salmonellae and S.aureus).
When no growth was obtained, a sample was withdrawn
and inoculated into fresh TSB or LB broth without added
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In addition, appearance of colonies was assessed by plating
10 or 50 μL samples to see if there were surviving cells that
were detectable by culture.
Determination of growth rates, generation times,
and number of generations
CFS that showed strong inhibition was selected for each
test bacterium and added at the lower inhibitory propor-
tion (30% for L. monocytogenes, 20% for S.aureus and
20% for Salmonella MI1, and S. enterica). Then, rate
of growth was quantified by both turbidity measurement
and plating on agar media at two hr intervals starting
from one hr after incubation of inoculated cultures and
continuing during the exponential growth phase. The
generation times (G) were calculated from the relation-
ship G = ln2/k, where,
k growth rateð Þ ¼ LogN1−LogN0
 
2:303ð Þ =T1−T0;
with N1 being the number of bacteria at time T1 (end-
point) and N0 being the number of bacteria at time T0
(start of logarithmic growth phase). Number of genera-
tions (N) was obtained from:
N ¼ LogN1−Log N0ð Þ=Log 2:
Each experiment was conducted three independent
times and data represent the averages of these experi-
ments. The Wilcoxon Rank Sum test was used to deter-
mine if significant differences exist between means of
bacterial numbers (CFUs) of control and experimental
cultures.
Test of MRS effect
To test if any of the components of the pure MRS broth
itself could have role in the inhibition, fresh MRS broth
was added to the TSB or LB broth to 50% (v/v) propor-
tion (in co-cultures) and inoculated with the target bac-
teria and the growth compared to those of the controls
(i.e., those grown in 100% TSB or LB).
Results
The pH of the CFSs before pH adjustment were in the
range of 4.5-4.8. Only CFS3 and CFS4 obtained from the
four selected isolates and the Labmix exhibited inhibi-
tory activity; i.e., pH-adjusted CFSs were ineffective in
inhibition. Inhibitory effect was not abolished by treat-
ment with the protease. The selected isolates were tenta-
tively identified as total LAB and Lactococcus sp. (both
isolated from fermented milk), Streptococcus thermo-
philus (isolated from Teff ) and a yeast species isolated
from ananas.Effect of CFS on growth rates and generation times
In the presence of CFS, both growth rates and number
of generations were significantly reduced when com-
pared to those of the controls. Thus, the growth rates of
L. monocytogenes, MI1 and S. aureus experimental cul-
tures were reduced by 40%, 38% and 32% respectively in
comparison to those of their respective controls. Ac-
cordingly, the number of generations of the experimen-
tal cultures decreased by the same percentage points as
did the growth rates (P < 0.05). Conversely, the gener-
ation times of experimental cultures of the three bacteria
were significantly increased compared to their respective
controls (by 164%, 162% and 147% respectively). Overall,
MI1 (the milk isolate) had the highest growth rate, the
shortest generation time and the highest number of gen-
erations among the three bacteria in both the control
and experimental conditions (Table 1).
Simultaneous cultures
Plating 1 μL of dilutions of the L. monocytogenes co-
cultures on day 3 from the 50% CFS proportions of total
LAB, Lactococcus and Labmix gave no colonies, but after
plating 50 μL, 2.26 × 102 CFU mL−1 was obtained from
the Lactococcus CFS co-culture only. However, on day 3,
the average CFU from the control cultures was 1.71 ×
109 ± 4.77 × 108, an increase of 4.72 Log units over that
of day 0 control CFU. CFS from S. thermophiles and
yeast were less effective against L. monocytogenes but
nonetheless, the CFU obtained were significantly less
than the control (P ≤ 0.05) (Table 2A).
The S. enterica co-cultures exhibited the most dra-
matic reductions in CFU by day 3, and this was obtained
with the lowest CFS proportions (12.5%). The 12.5%
proportions of all CFSs caused a > 99% reduction in
CFU compared to the day 3 control CFUs, while the latter
increased by > 140 fold over that of day 0 CFU (i.e., an in-
crease of 2.15 Log units (Table 2B).
The control co-culture of MI1 continued to grow into
day 3 of culture by an increase of 4.47 Log units relative
to that of day 0 control (2.06 × 109 ± 1.58 × 108 vs 7.05 ×
104 ± 2.64 × 103). Among the 12.5% CFS-treated cultures,
Labmix and S. thermophilus caused the highest reduc-
tions in CFU, by 4.83 and 3.83 Log CFU mL−1 units re-
spectively, relative to the day 3 control (P ≤ 0.05). With
the highest CFS proportions tested (25%), the CFU were
reduced to zero or to below the level of the day zero
CFUs except for that of the yeast CFS (Table 3A). Since
zero CFU were obtained for some of the samples with
25% CFS proportions, increased volumes (10 or 50 μL
instead of the usual 1 μL) were subsequently plated on
day 5 for those cultures which gave zero CFU on day 3.
The result was that either the colonies so obtained were
extremely small compared to those from the control or
still no CFU were obtained.
Table 1 Growth rates and generation times and numbers of bacteria in control (CFS-free) and experimental (CFS-treated)
cultures
Bacteria Growth rate (k, hr−1) Generation time (minutes) No of generations
Control Exp. Control Exp. Control Exp.
L. monocytogenes 1.9 ± 0.002 1.15 ± 0.006 21.8 ± 0.025 35.9 ± 0.004 10.97 ± 0.013 6.65 ± 0.03
Salmonella (MI1) 2.9 ± 0.03 1.8 ± 0.015 14.3 ± 0.14 23.2 ± 0.20 16.73 ± 0.17 9.83 ± 0.59
S. aureus 1.64 ± 0.008 1.12 ± 0.09 25.4 ± 0.13 37.4 ± 3.19 9.46 ± 0.033 6.45 ± 0.55
(Exp. = Experimental).
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portions were also seen with S. aureus co-cultures, exhi-
biting the highest reductions at the 25% CFS, but even
the 12.5% CFS also caused significant reductions in CFU
at day 3 relative to that of the day 3 control (P ≤ 0.05)
(Table 3B). Comparing CFUs obtained from correspond-
ing CFS proportions, the 12.5% and 25% total LAB CFSs
resulted in 2.05 and 4.19 Log decreases respectively on
day 3 relative to the day 3 control; while that of the con-
trol increased by 4.21 Log units relative to the initial,
day 0 control. Similarly, the 12.5 and 25% CFS of Lacto-
coccus caused 1.24 and 3.09 Log units decrease relative
the day 3 control CFU.
Delayed cultures
The L. monocytogenes delayed culture was more resistant
to the CFSs than the other bacteria. However, it was
kept to at least below the control CFU level by day 1.5
and most cultures gave CFU that were significantly less
than the control (P ≤ 0.05) (Table 4A). There was noTable 2 Log CFU mL−1 of CFS-treated L. monocytogenes (A) an
A. L. monocytogenes
Day CFS (%) CFS
Total LAB Lactococcus
0 0 4.00 × 104 ± 2.6
3 0 1.71 × 109 ± 4.7
25 1.90 × 108 ± 1.13 × 108⊕ 8.00 × 107 ± 2.83 × 107 1
50 0.0Ω 2.26 × 102 ± 3.05 × 101♦
B. S. enterica
Day CFS (%) CFS
Total LAB Lactococcus
0 0 1.30 × 106 ± 1.0
3 0 1.83 × 108 ± 1.1
12.5 2.50 × 102 ± 7.0 × 101 5.00 × 104 ± 0.0∑ 4
Comparisons were made between CFUs from all CFS-treated co-cultures on day 3 and
co-cultures are for reference only, i.e., to indicate both initial CFUs and that growth occ
⊕For L. monocytogenes, this value was significantly less than its respective day 3 co
less than this value, they were also significantly less than the day 3 control CFU.
♦ - Obtained by plating 50 μL (undiluted) instead of the usual 1 μL of 10−6 or 10−4
Ω - This value was zero even after plating 50 μL direct from culture instead of 1 μL
∑For S. enterica, this value was significantly less than its respective day 3 control CFU
than this value, they were also significantly less than the day 3 control CFU.
ND – Not done.CFS proportion-dependent progressive decrease in CFU
of L. monocytogenes delayed cultures.
The S. aureus delayed cultures were insensitive to the
tested CFSs at 20%. However, all CFSs at 25% reduced
the CFU significantly, except that of total LAB (P ≤ 0.05)
(Table 4B).
With the Salmonella MI1 delayed cultures, day 1.5 CFU
from treated cultures were less than the day 1.5 control by
1.07 – 1.47 Log units. (Table 4C), i.e., all day 1.5 experi-
mental CFUs were significantly less than the day 1.5 con-
trol (P ≤ 0.05).
There was no CFS inhibitory effect on growth of S.
enterica delayed cultures as there was no difference at
all in CFUs between those grown in LB broth with or
without any of the CFSs.
MRS effect
For all target bacteria, there was no difference in the
number of CFU obtained in the co-cultures contain-
ing 50% MRS broth (i.e., 50% MRS + 50% TSB or LB)d S. enterica (B) co-cultures
Labmix S. thermophilus Yeast sp.
4 × 103
7 × 108
.50 × 108 ± 1.41 × 107 3.60 × 107 ± 1.41 × 106 1.82 × 107
0.0Ω 6.25 × 104 ± 1.06 × 104 6.80 × 107 ± 2.83 × 106
Labmix S. thermophilus Yeast sp.
0 × 105
5 × 107
.20 × 103 ± 4.24 × 102 8.40 × 103 ± 5.65 × 102 ND
CFU from the control (0% CFS) on day 3. CFUs from the day 0 control (0% CFS)
urs in the absence of CFS treatment.
ntrol CFU (P <0.05). Since all other experimental CFUs of all CFSs on day 3 were
dilutions.
of dilutions.
(P <0.05). Since all other experimental CFUs of all CFSs on day 3 were less
Table 3 Log CFU mL−1 of CFS-treated Salmonella (MI1) (A) and S. aureus (B) co-cultures
A. Salmonella MI1
Day CFS (%) CFS
Total LAB Lactococcus Labmix S. thermophilus Yeast sp.
0 0 7.05 × 104 ± 2.64 × 103
3 0 2.06 × 109 ± 1.58 × 108
12.5 1.90 × 107 ± 1.41 × 106Δ 9.90 × 107 ± 1.41 × 106 3.06 × 104 ± 8.48 × 102* 3.05 × 105 ± 7.07 × 103 2.10 × 108 ± 2.82 × 107∞
25 0.0 3.20 × 104* 0.0** 3.70 × 102 ± 9.8 × 101 2.51 × 107 ± 1.41 × 105
B. S. aureus
Day CFS (%) CFS
C. Total LAB Lactococcus Labmix S. thermophilus Yeast sp.
0 0 6.27 × 104 ± 6.43 × 103
3 0 1.05 × 109 ± 2.12 × 108
12.5 9.30 × 106 ± 1.27 × 106 6.00 × 107 ± 4.24 × 107θ 5.15 × 105 ± 2.12 × 104 1.95 × 107 ± 1.41 × 106 5.40 × 107 ± 2.82 × 106
25 6.80 × 104 ± 1.69 × 104 8.50 × 105 ± 4.94 × 105 1.09 × 105 ± 7.07 × 103 0.0 2.37 × 107 ± 2.40 × 106
Comparisons were made between CFUs from all CFS-treated co-cultures on day 3 and CFU from the control on day 3. CFUs from the day 0 control (0% CFS)
co-cultures are for reference only, i.e., to indicate both initial CFUs and that growth occurs in the absence of CFS treatment.
Δ - Colonies were extremely small even after prolonged incubation for 48 hrs.
* - Obtained by plating of 50 μL (undiluted) instead of the previous 1 μL (undiluted) plating.
** - This value was 0.0 even after plating 10 or 50 μL directly (without dilution) instead of 1 μL.
∞For Salmonella (MI1), this value was significantly less than its respective day 3 control CFU (P ≤ 0.05). Since all other experimental CFUs of all CFSs on day 3 were
less than this value, they were also significantly less than the day 3 CFU.
θFor S. aureus, this value was significantly less than its respective day 3 control CFU (P ≤ 0.05). Since all other experimental CFUs of all CFSs on day 3 were less
than this value, they were also significantly less than the day 3 CFU.
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or LB).
Discussion
In this work, CFSs derived from selected LAB and yeast
broth cultures were tested for inhibitory effect on vari-
ous bacteria in cultures to which CFS were added in
simultaneous or delayed mode. Inhibitory effect was
much stronger in co-cultures. All test bacteria were
inhibited at all CFS proportions tested in co-cultures,
with stronger inhibition at the higher CFS propor-
tions. The inhibition of S. enterica in co-culture is
particularly noteworthy for two reasons: the initial
(day 0) CFU was the highest among those of all the
target bacteria and the inhibition was exerted by the
lowest CFs proportion.
The delayed cultures showed that even with late
addition of CFS, it was possible to retard the growth, in
most cases, to at least below the control level at the end
of the experiment.
The inhibitory action of the CFSs was not abolished by
treatments with proteinase K. The inhibitory substance
(s) in the CFSs were heat-resistant as activity was not
abolished after heat treatment. They do not appear to be
of the class III non-bacteriocin-like lytic proteins [25,26]
due to their heat resistance. They were also equally ac-
tive against both Gram-positive and –negative bacteria.
Bacteriocin-like, heat-stable substances active againsteither or both groups of bacteria have been described
[27-30]. These results suggest the non-protein (i.e., non-
bacteriocin) nature of the active substances within the
CFSs. Treatment with catalase did not result in abolition
of activity either, which might indicate hydrogen perox-
ide was not responsible for the observed activities. There
have been some reports about the unsuitability of MRS
broth for growth and production of LAB CFS to be used
in inhibition of certain pathogens due to its inhibition of
production of hydrogen peroxide [31,32]. The recom-
mended medium instead was LAPTg broth. Accordingly,
this broth was used here to grow LAB and obtain the
CFS. The CFS so obtained did not result in enhanced in-
hibition of L. monocytogenes or Salmonellae or S. aureus.
In fact, growth of these bacteria in CFS obtained from
LAPTg broth-grown LAB was equal to or slightly higher
than CFS from MRS broth-grown LAB. These results
may be suggestive of a minor, if any, role for H2O2 in
the observed inhibition in MRS broth CFS. Catalase
treatment of the CFS obtained from the LAPTg broth
culture did not result in enhanced growth of the target
bacteria either. In addition, H2O2 in the CFSs would
have had little, if any, role in inhibition, at least in the
cases of L. monocytogenes and S. aureus, as these organ-
isms are catalase producers themselves. Both of these
findings (the non-protein and non-H2O2 nature of the
active substances) bear an interesting similarity to the
results of Bleicher et al. [33]. The inhibition observed in
Table 4 Log CFU mL−1 of CFS-treated L. monocytogenes (A), S. aureus (B) and Salmonella (MI1) (C) delayed cultures
A. L. monocytogenes
Day CFS (%) CFS
Total LAB Lactococcus Labmix S. thermophilus
0 0 1.38 × 106 ± 2.56 × 104
30 1.45 × 106 ± 1.06 × 104
40 1.88 × 106 ± 1.52 × 104
50 1.68 × 106 ± 2.82 × 104
1.5 0 1.28 × 109 ± 7.03 × 108
30 3.35 × 108 ± 3.53 × 107* 8.50 × 108 ± 7.07 × 107** 2.05 × 108 ± 7.07 × 106* 4.40 × 108 ± 8.48 × 107**
40 ND 1.55 × 108 ± 3.53 × 107* 4.15 × 108 ± 7.77 × 107* 5.80 × 108 ± 2.82 × 107**
50 5.25 × 108 ± 7.07 × 106** 8.50 × 108 ± 7.07 × 106** 2.90 × 108 ± 1.41 × 107* 2.55 × 108 ± 6.36 × 107*
B. S. aureus
Day CFS (%) CFS
Total LAB Lactococcus Labmix S. thermophilus
0 0 4.30 × 106 ± 1.76 × 104
20 3.57 × 106 ± 3.53 × 104
25 3.41 × 106 ± 3.53 × 104
1.5 0 2.20 × 108 ± 4.24 × 107
20 8.50 × 107 ± 7.07 × 106* 8.60 × 108 ± 8.48 × 107** 2.85 × 108 ± 2.12 × 107** 2.15 × 108 ± 7.07 × 106**
25 2.20 × 108 ± 8.48 × 107** 7.50 × 107 ± 3.53 × 107* 5.00 × 107 ± 0.0* 9.00 × 107 ± 2.82 × 107*
C. Salmonella MI1
Day CFS (%) CFS
Total LAB Lactococcus Labmix S. thermophilus
0 0 1.55 × 106 ± 4.24 × 104
20 1.75 × 106 ± 1.06 × 104
25 1.56 × 106 ± 2.82 × 104
1.5 0 5.90 × 108 ± 3.39 × 107
20 2.00 × 107 ± 1.41 × 107* 5.00 × 107 ± 1.41 × 107* 2.00 × 107 ± 1.41 × 107* 2.50 × 107 ± 7.07 × 106*
25 ND 4.50 × 107 ± 2.12 × 107* 2.00 × 107 ± 1.41 × 107* 2.50 × 107 ± 7.07 × 106*
For each bacterium, those experimental CFUs that are significantly less than the respective day 1.5 control CFU are marked with (*), while those that are not are
marked with (**). ND- not done.
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low pH alone as most of the 17 CFSs tested before pH
adjustment were not effective. This ascribes the inhibi-
tory effect largely, if not totally, to non-bacteriocin me-
tabolites secreted by the LAB isolates into the growth
medium. It is possible that there was a combined syner-
gistic effect between low pH and the metabolites. Bio-
chemical characterization of the substances is needed to
ascertain their exact nature.
The effects of the CFSs in inhibiting the bacterial path-
ogens were transitory, as was also seen in the work of
others [34,35]. Colonies from experimental cultures were
both fewer in numbers and much smaller in size. Upon
transfer of samples from apparently completely inhibited
cultures to fresh broth medium, however, growth oc-
curred. After a second serial transfer, the resultingcolonies attained comparable sizes to those from control
cultures, indicating some bacterial populations remained
viable but not culture-detectable.
Conclusions
Pathogens such as L. monocytogenes with tolerance or
resistance to common food preservation methods and
disinfectants, exceptional adaptation to changing envi-
ronments and persistence in food-processing facilities
continue to pose risk to human health. The antibiotic ar-
senal is limited, and bacterial pathogens often develop
resistance to newly introduced antibiotics. These facts
dictate that, along with new antibiotics, suitable patho-
gen control alternatives that are safe and efficacious are
needed. LAB are suitable candidates in the search for
these alternatives, and globally, some are already used in
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http://www.biomedcentral.com/1756-0500/7/606probiotic formulations. In this work, it was demon-
strably possible to significantly retard the growth of the
tested bacteria by LAB metabolites. To the best of our
knowledge, we are not aware of reports of studies on
local fermented foods that simultaneously identified the
LAB species and pathogenic bacteria within the specific
fermented foods and studied the interactions between
the two groups of bacteria. Similar other studies have
been done elsewhere, but they do not necessarily apply
universally. Even members of the same bacterial species
can have contrasting virulence characters (an example
would be the Enterococci: Enterococcus faecalis, a pro-
biotic strain and a pathogenic clinical isolate of Entero-
coccus faecalis).
This study was limited in scope, but we intend to fur-
ther this work by focusing not only on the antimicrobial
properties of the LAB, but also isolation and identifica-
tion of the metabolites, their mechanisms of action, suit-
able modes of application, other potential applications,
safety issues including the presence of virulence factors
and transferable antibiotic resistance and comparison to
standard type strains. In addition, a medium-to-long
term goal would be to promote and advance probiotic
science in our setting, which is virtually unknown at this
time. For this, full characterization of the resident mi-
crobial flora within fermented foods and drinks of local
origin is an imperative.
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